MCID: END032
MIFTS: 22

Endometrial Clear Cell Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Clear Cell Adenocarcinoma

MalaCards integrated aliases for Endometrial Clear Cell Adenocarcinoma:

Name: Endometrial Clear Cell Adenocarcinoma 12 15 73
Clear Cell Carcinoma of Endometrium 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5299
NCIt 50 C8028
UMLS 73 C0279765

Summaries for Endometrial Clear Cell Adenocarcinoma

Disease Ontology : 12 An endometrial adenocarcinoma that is characterized by the presence of cells with clear cytoplasm.

MalaCards based summary : Endometrial Clear Cell Adenocarcinoma, also known as clear cell carcinoma of endometrium, is related to adenocarcinoma and clear cell adenocarcinoma. An important gene associated with Endometrial Clear Cell Adenocarcinoma is CTSD (Cathepsin D), and among its related pathways/superpathways are Circadian entrainment and Prolactin Signaling Pathway. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, ovary and thyroid.

Related Diseases for Endometrial Clear Cell Adenocarcinoma

Diseases related to Endometrial Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.0
2 clear cell adenocarcinoma 10.0
3 colonic disease 9.8 CTSD ESR1
4 endometrial adenocarcinoma 9.8 CTSD ESR1
5 breast ductal carcinoma 9.8 CTSD ESR1
6 breast adenocarcinoma 9.8 CTSD ESR1
7 breast disease 9.8 CTSD ESR1
8 endometrial cancer 9.7 CTSD ESR1

Graphical network of the top 20 diseases related to Endometrial Clear Cell Adenocarcinoma:



Diseases related to Endometrial Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Endometrial Clear Cell Adenocarcinoma

Drugs & Therapeutics for Endometrial Clear Cell Adenocarcinoma

Drugs for Endometrial Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Epirubicin Approved Phase 3 56420-45-2 41867
7
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
8
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
9 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
10 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
11 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
12 Adjuvants, Immunologic Phase 3,Phase 1
13 Immunologic Factors Phase 3,Phase 2,Phase 1
14 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
15 Antimitotic Agents Phase 3,Phase 2,Phase 1
16 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
17 Hypoglycemic Agents Phase 2, Phase 3
18
Gemcitabine Approved Phase 2 95058-81-4 60750
19
Nintedanib Approved Phase 2 656247-17-5 56843413
20
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
21
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
22
Everolimus Approved Phase 2 159351-69-6 6442177
23
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
25
Dasatinib Approved, Investigational Phase 2,Phase 1 302962-49-8 3062316
26
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
27
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
29
Cediranib Investigational Phase 2 288383-20-0 9933475
30
Maleic acid Experimental Phase 2 110-16-7 444266
31
Trebananib Investigational Phase 2 894356-79-7
32 Citrate Phase 2
33 Calcium, Dietary Phase 2
34 Anticoagulants Phase 2
35 Chelating Agents Phase 2
36 Antiviral Agents Phase 2,Phase 1
37 Immunosuppressive Agents Phase 2
38 Antimetabolites Phase 2
39 Anti-Infective Agents Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 2
41 Protein Kinase Inhibitors Phase 2,Phase 1
42 Immunoglobulins Phase 2,Phase 1
43 Immunoglobulin Fc Fragments Phase 2
44 Antibodies Phase 2,Phase 1
45 tyrosine Phase 2
46 Mitogens Phase 2,Phase 1
47 Angiogenesis Inhibitors Phase 2,Phase 1
48 Angiogenesis Modulating Agents Phase 2,Phase 1
49 Immunoglobulin G Phase 2,Phase 1
50 Antibodies, Monoclonal Phase 2,Phase 1

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
4 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
5 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
6 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
7 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
8 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
9 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
10 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
11 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
12 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
13 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
14 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
15 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
16 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
17 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
18 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
19 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
20 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
21 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
22 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
23 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
24 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
25 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
26 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
27 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
28 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
29 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
30 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
31 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
32 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2 Dasatinib
33 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
34 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
35 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
36 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
37 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
38 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
39 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
40 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Recruiting NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
41 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
42 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 1 Trametinib;Uprosertib
43 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
44 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
45 PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer Active, not recruiting NCT01737619 Not Applicable Indocyanine Green Solution

Search NIH Clinical Center for Endometrial Clear Cell Adenocarcinoma

Genetic Tests for Endometrial Clear Cell Adenocarcinoma

Anatomical Context for Endometrial Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Endometrial Clear Cell Adenocarcinoma:

41
Lymph Node, Ovary, Thyroid, Colon, Breast

Publications for Endometrial Clear Cell Adenocarcinoma

Articles related to Endometrial Clear Cell Adenocarcinoma:

# Title Authors Year
1
Endometrial clear cell adenocarcinoma diagnosed by endometrial cytological examination: two cases report. ( 21319323 )
2011

Variations for Endometrial Clear Cell Adenocarcinoma

Cosmic variations for Endometrial Clear Cell Adenocarcinoma:

9 (show top 50) (show all 398)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6904337 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 5
2 COSM10709 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 17:7674241-7674241 5
3 COSM44063 TP53 endometrium,NS,carcinoma,adenocarcinoma c.389T>G p.L130R 17:7675223-7675223 5
4 COSM10704 TP53 endometrium,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 5
5 COSM11073 TP53 endometrium,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 17:7670685-7670685 5
6 COSM10663 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 5
7 COSM44622 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 17:7674269-7674269 5
8 COSM10654 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 5
9 COSM45035 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 5
10 COSM43545 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 17:7675109-7675109 5
11 COSM6932 TP53 endometrium,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 17:7674230-7674230 5
12 COSM10656 TP53 endometrium,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 5
13 COSM43596 TP53 endometrium,NS,carcinoma,adenocarcinoma c.841G>A p.D281N 17:7673779-7673779 5
14 COSM5154 PTEN endometrium,NS,carcinoma,adenocarcinoma c.697C>T p.R233* 10:87957915-87957915 5
15 COSM5219 PTEN endometrium,NS,carcinoma,adenocarcinoma c.388C>G p.R130G 10:87933147-87933147 5
16 COSM5312 PTEN endometrium,NS,carcinoma,adenocarcinoma c.895G>T p.E299* 10:87960987-87960987 5
17 COSM5106 PTEN endometrium,NS,carcinoma,adenocarcinoma c.335T>C p.L112P 10:87933094-87933094 5
18 COSM5065 PTEN endometrium,NS,carcinoma,adenocarcinoma c.403A>G p.I135V 10:87933162-87933162 5
19 COSM5039 PTEN endometrium,NS,carcinoma,adenocarcinoma c.518G>A p.R173H 10:87952143-87952143 5
20 COSM5159 PTEN endometrium,NS,carcinoma,adenocarcinoma c.733C>T p.Q245* 10:87957951-87957951 5
21 COSM5115 PTEN endometrium,NS,carcinoma,adenocarcinoma c.155A>G p.D52G 10:87894100-87894100 5
22 COSM5033 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>A p.R130Q 10:87933148-87933148 5
23 COSM5943 PTEN endometrium,NS,carcinoma,adenocarcinoma c.634+3A>C p.? 10:87952262-87952262 5
24 COSM5276 PTEN endometrium,NS,carcinoma,adenocarcinoma c.386G>T p.G129V 10:87933145-87933145 5
25 COSM5105 PTEN endometrium,NS,carcinoma,adenocarcinoma c.284C>T p.P95L 10:87933043-87933043 5
26 COSM5212 PTEN endometrium,NS,carcinoma,adenocarcinoma c.319G>T p.D107Y 10:87933078-87933078 5
27 COSM5108 PTEN endometrium,NS,carcinoma,adenocarcinoma c.209T>C p.L70P 10:87925557-87925557 5
28 COSM5165 PTEN endometrium,NS,carcinoma,adenocarcinoma c.519C>T p.R173R 10:87952144-87952144 5
29 COSM5215 PTEN endometrium,NS,carcinoma,adenocarcinoma c.356T>A p.V119D 10:87933115-87933115 5
30 COSM5107 PTEN endometrium,NS,carcinoma,adenocarcinoma c.71A>G p.D24G 10:87864540-87864540 5
31 COSM5216 PTEN endometrium,NS,carcinoma,adenocarcinoma c.389G>T p.R130L 10:87933148-87933148 5
32 COSM5235 PTEN endometrium,NS,carcinoma,adenocarcinoma c.218A>T p.E73V 10:87931054-87931054 5
33 COSM5299 PTEN endometrium,NS,carcinoma,adenocarcinoma c.271G>T p.E91* 10:87933030-87933030 5
34 COSM5236 PTEN endometrium,NS,carcinoma,adenocarcinoma c.275A>T p.D92V 10:87933034-87933034 5
35 COSM5048 PTEN endometrium,NS,carcinoma,adenocarcinoma c.196A>G p.K66E 10:87925544-87925544 5
36 COSM937333 POLE endometrium,NS,carcinoma,adenocarcinoma c.857C>G p.P286R 12:132676598-132676598 5
37 COSM937331 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>T p.S297F 12:132676565-132676565 5
38 COSM5031089 POLE endometrium,NS,carcinoma,adenocarcinoma c.890C>A p.S297Y 12:132676565-132676565 5
39 COSM760 PIK3CA endometrium,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 3:179218294-179218294 5
40 COSM12597 PIK3CA endometrium,NS,carcinoma,adenocarcinoma c.3145G>C p.G1049R 3:179234302-179234302 5
41 COSM2726759 PHF6 endometrium,NS,carcinoma,adenocarcinoma c.635G>A p.C212Y 23:134413872-134413872 5
42 COSM13396 MSH6 endometrium,NS,carcinoma,adenocarcinoma c.1723G>T p.D575Y 2:47799706-47799706 5
43 COSM6904333 MSH6 endometrium,NS,carcinoma,adenocarcinoma c.3787C>T p.R1263C 2:47806344-47806344 5
44 COSM532 KRAS endometrium,NS,carcinoma,adenocarcinoma c.38G>A p.G13D 12:25245347-25245347 5
45 COSM516 KRAS endometrium,NS,carcinoma,adenocarcinoma c.34G>T p.G12C 12:25245351-25245351 5
46 COSM521 KRAS endometrium,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 5
47 COSM520 KRAS endometrium,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 12:25245350-25245350 5
48 COSM517 KRAS endometrium,NS,carcinoma,adenocarcinoma c.34G>A p.G12S 12:25245351-25245351 5
49 COSM535 KRAS endometrium,NS,carcinoma,adenocarcinoma c.39C>G p.G13G 12:25245346-25245346 5
50 COSM1562184 KRAS endometrium,NS,carcinoma,adenocarcinoma c.25G>A p.V9I 12:25245360-25245360 5

Expression for Endometrial Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Clear Cell Adenocarcinoma.

Pathways for Endometrial Clear Cell Adenocarcinoma

Pathways related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.03 CTSD ESR1
2
Show member pathways
11.41 CTSD ESR1
3 10.25 CTSD ESR1

GO Terms for Endometrial Clear Cell Adenocarcinoma

Sources for Endometrial Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....